AZ books 12 percent sales fall for Q4
AstraZeneca has booked a drop in revenues for the fourth quarter but says 2017 could be a ‘turning point’ for the firm as it comes to the end of its patent-expiry phase and begins its return to growth.
Read More
Tag: revenues
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
